Metastatic Prostate Cancer

Today we are recapping exciting GU data presented at the 2026 ASCO Annual Meeting in bladder cancer, kidney cancer, and prostate cancer. 

This week’s episode will be focusing on the 2026 ASCO Plenary that received a standing ovation, the RASolute 302 trial.The RASolute 302 trial is a landmark phase 3 study demonstrating that daraxonrasib doubled overall survival compared to chemotherapy in previously treated (2L) m ... Show More

Today we will be focusing on exciting data to come at the ASCO Annual Meeting in 2026 in Chicago, with a special focus on GU sessions, educational sessions & med ed sessions. 

New research on prostate cancer screening and diet. This episode features audio from: The Pros and Cons of Testing PSA Levels for Prostate Cancer Changing a Man’s Diet After a Prostate Cancer Diagnosis Natural Dietary Treatments for Enlarged Prostate BPH Visit the video pages for ... Show More

Send us Fan MailNinja Nerds!In this episode of the Ninja Nerd Podcast, Zach and Rob break down the essential clinical and pathophysiologic features of Prostate Cancer, one of the most common malignancies affecting men worldwide.We begin with the epidemiology and risk factors, hig ... Show More

What to look out for in bladder, prostate and renal cancer at this year's meeting. 

Olympic cyclist Sir Chris Hoy is calling for more prostate cancer testing after he was diagnosed with terminal cancer. Prostate cancer can often present without symptoms, and for people like Sir Chris, this can mean it isn't diagnosed until it has spread and become incurable. Unl ... Show More

Thomas Zilli discusses controversies around radiotherapy in prostate cancer. 

About 1 in 8 men will be diagnosed with prostate cancer during their lifetime. Join Lauren Bright Pacheco at the 2024 ASCO Annual Meeting in Chicago, as she investigates the advancements in prostate cancer care.  Dr. Mohammad Atiq shares ways innovative treatments are paving the ... Show More

Prostate cancer diagnostic guidelines aim to minimize over-diagnosis of clinically insignificant prostate cancer (Gleason6/GG1). The clinical question before us is how do we enable the best balance, helping to increase compliance with the biopsy recommendation for patients at hig ... Show More

One in eight men will be diagnosed with prostate cancer, and President Biden’s recent diagnosis has many people asking: Am I at risk? Should I get screened? Dr. Sanjay Gupta breaks down what to know about PSA tests, family history, screening age, and how your diet might factor in ... Show More

Among men aged 15 to 44 years, testicular tumours are the most common cancer diagnosed. And testicular cancer can cause considerable morbidity and mortality. So it is important that we get the diagnosis and management of this condition right. To find out more about this problem a ... Show More